Association of intracranial abnormalities with the development of epilepsy and drug-resistant epilepsy in patients with Parry-Romberg syndrome. Gunasekera, C. L, Middlebrooks, E. H, Burkholder, D. B, Chen, B., Sirven, J. I, Wong-Kisiel, L. C, Freund, B. E, Tatum, W. O, De la Garza-Ramos, C. C, Okromelidze, L., & Feyissa, A. M Journal of the neurological sciences, 442:120455, November, 2022. Place: Netherlands Publisher: Elsevier![Association of intracranial abnormalities with the development of epilepsy and drug-resistant epilepsy in patients with Parry-Romberg syndrome. [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Background: Epilepsy represents an essential component of Parry Romberg syndrome (PRS). This study aimed to identify clinical factors that influence the development of epilepsy and drug-resistant epilepsy (DRE) in PRS.; Methods: We retrospectively reviewed the medical records of eighty patients with PRS. Data including the age of onset for PRS, history of seizures, use and timing of immunotherapy, antiseizure medication use, and EEG and brain imaging findings were reviewed. For comparison with the patients with epilepsy (PRSe+) group, we selected 18 age and sex-matched controls from the patient without epilepsy (PRSe-) cohort using propensity score matching.; Results: Eighteen (22.5%) had epilepsy: 12 were female, and the median age was 14.5 years (range = 6-48 years). Eleven patients developed DRE. The median latency between the onset of cutaneous manifestations and diagnosis and timing and use of immunotherapy was similar between the PRSe + and PRSe- groups. Intracranial abnormalities were commonly seen in the PRSe + group (16 vs. 2, p \textless 0.01). White matter disease and ipsilateral atrophy were common among the PRSe + group. Timing and use of immunotherapy, epileptiform discharges, and brain imaging abnormalities did not differ between those with DRE and without.; Conclusions: The presence and degree of severity of ipsilateral brain abnormalities are risk factors for the development of epilepsy in PRS but not factors in predicting drug resistance. The timing of immunotherapy did not influence the development of PRSe + or DRE. Prospective studies are needed to identify biomarkers for epilepsy and assess the role of immunotherapy on seizure outcomes in PRSe + . (Copyright © 2022. Published by Elsevier B.V.)
@article{gunasekera_association_2022,
title = {Association of intracranial abnormalities with the development of epilepsy and drug-resistant epilepsy in patients with {Parry}-{Romberg} syndrome.},
volume = {442},
issn = {1878-5883},
url = {https://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=36242808&site=ehost-live&scope=site},
doi = {10.1016/j.jns.2022.120455},
abstract = {Background: Epilepsy represents an essential component of Parry Romberg syndrome (PRS). This study aimed to identify clinical factors that influence the development of epilepsy and drug-resistant epilepsy (DRE) in PRS.; Methods: We retrospectively reviewed the medical records of eighty patients with PRS. Data including the age of onset for PRS, history of seizures, use and timing of immunotherapy, antiseizure medication use, and EEG and brain imaging findings were reviewed. For comparison with the patients with epilepsy (PRSe+) group, we selected 18 age and sex-matched controls from the patient without epilepsy (PRSe-) cohort using propensity score matching.; Results: Eighteen (22.5\%) had epilepsy: 12 were female, and the median age was 14.5 years (range = 6-48 years). Eleven patients developed DRE. The median latency between the onset of cutaneous manifestations and diagnosis and timing and use of immunotherapy was similar between the PRSe + and PRSe- groups. Intracranial abnormalities were commonly seen in the PRSe + group (16 vs. 2, p {\textless} 0.01). White matter disease and ipsilateral atrophy were common among the PRSe + group. Timing and use of immunotherapy, epileptiform discharges, and brain imaging abnormalities did not differ between those with DRE and without.; Conclusions: The presence and degree of severity of ipsilateral brain abnormalities are risk factors for the development of epilepsy in PRS but not factors in predicting drug resistance. The timing of immunotherapy did not influence the development of PRSe + or DRE. Prospective studies are needed to identify biomarkers for epilepsy and assess the role of immunotherapy on seizure outcomes in PRSe + . (Copyright © 2022. Published by Elsevier B.V.)},
journal = {Journal of the neurological sciences},
author = {Gunasekera, Charlene L and Middlebrooks, Erik H and Burkholder, David B and Chen, Baibing and Sirven, Joseph I and Wong-Kisiel, Lily C and Freund, Brin E and Tatum, William O and De la Garza-Ramos, Cynthia C and Okromelidze, Lela and Feyissa, Anteneh M},
month = nov,
year = {2022},
note = {Place: Netherlands
Publisher: Elsevier},
keywords = {Adolescent, Adult, Atrophy/complications, Brain Diseases*/complications, Child, Drug Resistant Epilepsy*/complications, Drug Resistant Epilepsy*/diagnostic imaging, Drug Resistant Epilepsy*/therapy, Drug-resistant epilepsy, Epilepsy*/complications, Epilepsy*/diagnostic imaging, Epilepsy*/drug therapy, Facial Hemiatrophy*/complications, Facial Hemiatrophy*/diagnosis, Female, Hemifacial atrophy, Humans, Immune-mediated seizures, Intracranial abnormalities, Male, Middle Aged, Parry-Romberg syndrome, Retrospective Studies, Seizures/complications, Symptomatic epilepsy, White matter disease, Young Adult},
pages = {120455},
}
Downloads: 0
{"_id":"ZLMwTAHFLpzNK8Cm2","bibbaseid":"gunasekera-middlebrooks-burkholder-chen-sirven-wongkisiel-freund-tatum-etal-associationofintracranialabnormalitieswiththedevelopmentofepilepsyanddrugresistantepilepsyinpatientswithparryrombergsyndrome-2022","author_short":["Gunasekera, C. L","Middlebrooks, E. H","Burkholder, D. B","Chen, B.","Sirven, J. I","Wong-Kisiel, L. C","Freund, B. E","Tatum, W. O","De la Garza-Ramos, C. C","Okromelidze, L.","Feyissa, A. M"],"bibdata":{"bibtype":"article","type":"article","title":"Association of intracranial abnormalities with the development of epilepsy and drug-resistant epilepsy in patients with Parry-Romberg syndrome.","volume":"442","issn":"1878-5883","url":"https://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=36242808&site=ehost-live&scope=site","doi":"10.1016/j.jns.2022.120455","abstract":"Background: Epilepsy represents an essential component of Parry Romberg syndrome (PRS). This study aimed to identify clinical factors that influence the development of epilepsy and drug-resistant epilepsy (DRE) in PRS.; Methods: We retrospectively reviewed the medical records of eighty patients with PRS. Data including the age of onset for PRS, history of seizures, use and timing of immunotherapy, antiseizure medication use, and EEG and brain imaging findings were reviewed. For comparison with the patients with epilepsy (PRSe+) group, we selected 18 age and sex-matched controls from the patient without epilepsy (PRSe-) cohort using propensity score matching.; Results: Eighteen (22.5%) had epilepsy: 12 were female, and the median age was 14.5 years (range = 6-48 years). Eleven patients developed DRE. The median latency between the onset of cutaneous manifestations and diagnosis and timing and use of immunotherapy was similar between the PRSe + and PRSe- groups. Intracranial abnormalities were commonly seen in the PRSe + group (16 vs. 2, p \\textless 0.01). White matter disease and ipsilateral atrophy were common among the PRSe + group. Timing and use of immunotherapy, epileptiform discharges, and brain imaging abnormalities did not differ between those with DRE and without.; Conclusions: The presence and degree of severity of ipsilateral brain abnormalities are risk factors for the development of epilepsy in PRS but not factors in predicting drug resistance. The timing of immunotherapy did not influence the development of PRSe + or DRE. Prospective studies are needed to identify biomarkers for epilepsy and assess the role of immunotherapy on seizure outcomes in PRSe + . (Copyright © 2022. Published by Elsevier B.V.)","journal":"Journal of the neurological sciences","author":[{"propositions":[],"lastnames":["Gunasekera"],"firstnames":["Charlene","L"],"suffixes":[]},{"propositions":[],"lastnames":["Middlebrooks"],"firstnames":["Erik","H"],"suffixes":[]},{"propositions":[],"lastnames":["Burkholder"],"firstnames":["David","B"],"suffixes":[]},{"propositions":[],"lastnames":["Chen"],"firstnames":["Baibing"],"suffixes":[]},{"propositions":[],"lastnames":["Sirven"],"firstnames":["Joseph","I"],"suffixes":[]},{"propositions":[],"lastnames":["Wong-Kisiel"],"firstnames":["Lily","C"],"suffixes":[]},{"propositions":[],"lastnames":["Freund"],"firstnames":["Brin","E"],"suffixes":[]},{"propositions":[],"lastnames":["Tatum"],"firstnames":["William","O"],"suffixes":[]},{"propositions":["De","la"],"lastnames":["Garza-Ramos"],"firstnames":["Cynthia","C"],"suffixes":[]},{"propositions":[],"lastnames":["Okromelidze"],"firstnames":["Lela"],"suffixes":[]},{"propositions":[],"lastnames":["Feyissa"],"firstnames":["Anteneh","M"],"suffixes":[]}],"month":"November","year":"2022","note":"Place: Netherlands Publisher: Elsevier","keywords":"Adolescent, Adult, Atrophy/complications, Brain Diseases*/complications, Child, Drug Resistant Epilepsy*/complications, Drug Resistant Epilepsy*/diagnostic imaging, Drug Resistant Epilepsy*/therapy, Drug-resistant epilepsy, Epilepsy*/complications, Epilepsy*/diagnostic imaging, Epilepsy*/drug therapy, Facial Hemiatrophy*/complications, Facial Hemiatrophy*/diagnosis, Female, Hemifacial atrophy, Humans, Immune-mediated seizures, Intracranial abnormalities, Male, Middle Aged, Parry-Romberg syndrome, Retrospective Studies, Seizures/complications, Symptomatic epilepsy, White matter disease, Young Adult","pages":"120455","bibtex":"@article{gunasekera_association_2022,\n\ttitle = {Association of intracranial abnormalities with the development of epilepsy and drug-resistant epilepsy in patients with {Parry}-{Romberg} syndrome.},\n\tvolume = {442},\n\tissn = {1878-5883},\n\turl = {https://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=36242808&site=ehost-live&scope=site},\n\tdoi = {10.1016/j.jns.2022.120455},\n\tabstract = {Background: Epilepsy represents an essential component of Parry Romberg syndrome (PRS). This study aimed to identify clinical factors that influence the development of epilepsy and drug-resistant epilepsy (DRE) in PRS.; Methods: We retrospectively reviewed the medical records of eighty patients with PRS. Data including the age of onset for PRS, history of seizures, use and timing of immunotherapy, antiseizure medication use, and EEG and brain imaging findings were reviewed. For comparison with the patients with epilepsy (PRSe+) group, we selected 18 age and sex-matched controls from the patient without epilepsy (PRSe-) cohort using propensity score matching.; Results: Eighteen (22.5\\%) had epilepsy: 12 were female, and the median age was 14.5 years (range = 6-48 years). Eleven patients developed DRE. The median latency between the onset of cutaneous manifestations and diagnosis and timing and use of immunotherapy was similar between the PRSe + and PRSe- groups. Intracranial abnormalities were commonly seen in the PRSe + group (16 vs. 2, p {\\textless} 0.01). White matter disease and ipsilateral atrophy were common among the PRSe + group. Timing and use of immunotherapy, epileptiform discharges, and brain imaging abnormalities did not differ between those with DRE and without.; Conclusions: The presence and degree of severity of ipsilateral brain abnormalities are risk factors for the development of epilepsy in PRS but not factors in predicting drug resistance. The timing of immunotherapy did not influence the development of PRSe + or DRE. Prospective studies are needed to identify biomarkers for epilepsy and assess the role of immunotherapy on seizure outcomes in PRSe + . (Copyright © 2022. Published by Elsevier B.V.)},\n\tjournal = {Journal of the neurological sciences},\n\tauthor = {Gunasekera, Charlene L and Middlebrooks, Erik H and Burkholder, David B and Chen, Baibing and Sirven, Joseph I and Wong-Kisiel, Lily C and Freund, Brin E and Tatum, William O and De la Garza-Ramos, Cynthia C and Okromelidze, Lela and Feyissa, Anteneh M},\n\tmonth = nov,\n\tyear = {2022},\n\tnote = {Place: Netherlands\nPublisher: Elsevier},\n\tkeywords = {Adolescent, Adult, Atrophy/complications, Brain Diseases*/complications, Child, Drug Resistant Epilepsy*/complications, Drug Resistant Epilepsy*/diagnostic imaging, Drug Resistant Epilepsy*/therapy, Drug-resistant epilepsy, Epilepsy*/complications, Epilepsy*/diagnostic imaging, Epilepsy*/drug therapy, Facial Hemiatrophy*/complications, Facial Hemiatrophy*/diagnosis, Female, Hemifacial atrophy, Humans, Immune-mediated seizures, Intracranial abnormalities, Male, Middle Aged, Parry-Romberg syndrome, Retrospective Studies, Seizures/complications, Symptomatic epilepsy, White matter disease, Young Adult},\n\tpages = {120455},\n}\n\n\n\n","author_short":["Gunasekera, C. L","Middlebrooks, E. H","Burkholder, D. B","Chen, B.","Sirven, J. I","Wong-Kisiel, L. C","Freund, B. E","Tatum, W. O","De la Garza-Ramos, C. C","Okromelidze, L.","Feyissa, A. M"],"key":"gunasekera_association_2022","id":"gunasekera_association_2022","bibbaseid":"gunasekera-middlebrooks-burkholder-chen-sirven-wongkisiel-freund-tatum-etal-associationofintracranialabnormalitieswiththedevelopmentofepilepsyanddrugresistantepilepsyinpatientswithparryrombergsyndrome-2022","role":"author","urls":{"Paper":"https://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=36242808&site=ehost-live&scope=site"},"keyword":["Adolescent","Adult","Atrophy/complications","Brain Diseases*/complications","Child","Drug Resistant Epilepsy*/complications","Drug Resistant Epilepsy*/diagnostic imaging","Drug Resistant Epilepsy*/therapy","Drug-resistant epilepsy","Epilepsy*/complications","Epilepsy*/diagnostic imaging","Epilepsy*/drug therapy","Facial Hemiatrophy*/complications","Facial Hemiatrophy*/diagnosis","Female","Hemifacial atrophy","Humans","Immune-mediated seizures","Intracranial abnormalities","Male","Middle Aged","Parry-Romberg syndrome","Retrospective Studies","Seizures/complications","Symptomatic epilepsy","White matter disease","Young Adult"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/katiedillon","dataSources":["Qf74gub9z54CooHnE"],"keywords":["adolescent","adult","atrophy/complications","brain diseases*/complications","child","drug resistant epilepsy*/complications","drug resistant epilepsy*/diagnostic imaging","drug resistant epilepsy*/therapy","drug-resistant epilepsy","epilepsy*/complications","epilepsy*/diagnostic imaging","epilepsy*/drug therapy","facial hemiatrophy*/complications","facial hemiatrophy*/diagnosis","female","hemifacial atrophy","humans","immune-mediated seizures","intracranial abnormalities","male","middle aged","parry-romberg syndrome","retrospective studies","seizures/complications","symptomatic epilepsy","white matter disease","young adult"],"search_terms":["association","intracranial","abnormalities","development","epilepsy","drug","resistant","epilepsy","patients","parry","romberg","syndrome","gunasekera","middlebrooks","burkholder","chen","sirven","wong-kisiel","freund","tatum","de la garza-ramos","okromelidze","feyissa"],"title":"Association of intracranial abnormalities with the development of epilepsy and drug-resistant epilepsy in patients with Parry-Romberg syndrome.","year":2022}